您的位置：首页 > 论文页面
程序性死亡受体1及其配体1在与自身免疫相关的眼病中的研究进展
发表时间：2018-11-15 浏览量：1780 下载量：195
| 全部作者： | 吴绵绵，张智，郭芳，漆晨，张琰 |
| 作者单位： | 天津医科大学眼科医院，天津医科大学眼科研究所，天津医科大学眼视光学院 |
| 摘 要： | 程序性死亡受体1（programmed death receptor-1，PD-1）及其配体PD-L1作为负性共刺激因子，与机体免疫反应的调节密切相关。PD-1/PD-L1信号通路在肿瘤领域的机制研究已广泛开展，PD-1抗体刚刚获得了美国食品和药物管理局（Food and Drug Administration，FDA）的批准，可在部分肿瘤的免疫治疗中应用于临床。PD-1/PD-L1系统在眼部疾病的作用机制近年来也受到广泛关注，本文旨在对PD-1/PD-L1系统在自身免疫相关的眼部疾病中的致病机制和临床治疗效果进行总结，为自身免疫相关性眼病的治疗提供新思路。 |
| 关 键 词： | 生物化学；程序性死亡受体1（PD-1）；综述；程序性死亡受体配体1（PD-L1）；自身免疫性眼病 |
| Title： | Research advances of programmed death receptor-1 and its ligand 1 in the pathogenesis of autoimmune-related eye diseases |
| Author： | WU Mianmian, ZHANG Zhi, GUO Fang, QI Chen, ZHANG Yan |
| Organization： | Tianjin Medical University Eye Hospital, Tianjin Medical University Eye Institute, School of Optometry and Ophthalmology, Tianjin Medical University |
| Abstract： | Programmed death receptor-1 (PD-1) and its ligand PD-L1, as negative co-stimulatory molecules, are closely associated with the regulation of immune responses. The PD-1/PD-L1-mediated signaling pathway has been extensively studied in tumor biology. Furthermore, PD-1 monoclonal antibodies have just been approved by the Food and Drug Administration (FDA) in the US to be applied in clinical practice as an immunotherapy to certain types of tumors. In recent years, the mechanisms of PD-1/PD-L1 system in eye diseases have also drawn widespread attention. This review aims to summarize the pathogenic mechanisms and clinical therapeutic effects of PD-1/PD-L1 system in autoimmune-related eye diseases, providing new clues for the therapeutic modalities to the autoimmune-related eye diseases. |
| Key words： | biochemistry; programmed death receptor-1 (PD-1); review; programmed death receptor-ligand 1 (PD-L1); autoimmune eye diseases |
| 发表期数： | 2018年11月第21期 |
| 引用格式： | 吴绵绵，张智，郭芳，等. 程序性死亡受体1及其配体1在与自身免疫相关的眼病中的研究进展[J]. 中国科技论文在线精品论文，2018，11（21）：2106-2113. |
7
评论数 0请您登录
暂无评论
下载全文
多维论文